VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
-2.24%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.69B
AUM Growth
+$1.69B
(+33%)
Cap. Flow
+$495M
Cap. Flow
% of AUM
29.37%
Top 10 Holdings %
Top 10 Hldgs %
42.19%
Holding
93
New
24
Increased
32
Reduced
12
Closed
18
Top Buys
| 1 |
Merck
MRK
|
$79.6M |
| 2 |
Nuvalent
NUVL
|
$47M |
| 3 |
Vera Therapeutics
VERA
|
$45.5M |
| 4 |
Cytokinetics
CYTK
|
$40M |
| 5 |
Ascendis Pharma
ASND
|
$37.2M |
Top Sells
| 1 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$63.9M |
| 2 |
Insmed
INSM
|
$48.3M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$33.8M |
| 4 |
uniQure
QURE
|
$30.5M |
| 5 |
Janux Therapeutics
JANX
|
$22M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Jazz Pharmaceuticals
JAZZ
$7.75B
| $120M | 7.12% | 975,000 +75,000 | +8% | +$9.24M |
|
|
2
Cytokinetics
CYTK
$4.23B
| $111M | 6.55% | 2,350,000 +850,000 | +57% | +$40M |
|
|
3
Merck
MRK
$210B
| $79.6M | 4.72% | +800,000 | New | +$79.6M |
|
|
4
Ascendis Pharma
ASND
$11.8B
| $71.6M | 4.24% | 520,000 +270,000 | +108% | +$37.2M |
|
5
Ultragenyx Pharmaceutical
RARE
$2.89B
| $63.1M | 3.74% | 1,500,000 +750,000 | +100% | +$31.6M |
|
|
6
Insmed
INSM
$28.8B
| $62.1M | 3.68% | 900,000 -700,000 | -44% | -$48.3M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $56.5M | 3.35% | 860,000 +460,000 | +115% | +$30.2M |
|
|
8
uniQure
QURE
$896M
| $53.4M | 3.17% | 3,025,000 -1,725,000 | -36% | -$30.5M |
|
9
Soleno Therapeutics
SLNO
$3.6B
| $47.6M | 2.82% | 1,060,000 +340,000 | +47% | +$15.3M |
|
|
10
Nuvalent
NUVL
$5.52B
| $47M | 2.78% | +600,000 | New | +$47M |
|
11
Structure Therapeutics
GPCR
$1.11B
| $46.8M | 2.77% | 1,725,000 +575,000 | +50% | +$15.6M |
|
|
12
Vera Therapeutics
VERA
$1.38B
| $45.5M | 2.7% | +1,075,000 | New | +$45.5M |
|
13
Immatics
IMTX
$619M
| $44.6M | 2.65% | 6,275,000 +2,525,000 | +67% | +$18M |
|
14
KalVista Pharmaceuticals
KALV
$678M
| $40.4M | 2.4% | 4,770,000 +770,000 | +19% | +$6.52M |
|
15
Geron
GERN
$893M
| $38.9M | 2.31% | 11,000,000 +9,950,000 | +948% | +$35.2M |
|
16
Astria Therapeutics
ATXS
$349M
| $37.4M | 2.22% | 4,180,000 +180,000 | +5% | +$1.61M |
|
17
Arcellx
ACLX
$3.85B
| $36.4M | 2.16% | 475,000 -200,000 | -30% | -$15.3M |
|
18
Sanofi
SNY
$121B
| $36.2M | 2.14% | 750,000 +600,000 | +400% | +$28.9M |
|
19
GSK
GSK
$79.9B
| $33.8M | 2.01% | 1,000,000 +700,000 | +233% | +$23.7M |
|
20
Savara
SVRA
$567M
| $33.1M | 1.96% | 10,775,000 +2,685,000 | +33% | +$8.24M |
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $31.8M | 1.88% | 810,000 -15,000 | -2% | -$588K |
|
22
Amicus Therapeutics
FOLD
$2.34B
| $31.6M | 1.87% | +3,350,000 | New | +$31.6M |
|
23
AstraZeneca
AZN
$248B
| $31.1M | 1.85% | +475,000 | New | +$31.1M |
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $30.4M | 1.8% | +250,000 | New | +$30.4M |
|
25
Madrigal Pharmaceuticals
MDGL
$9.76B
| $29.3M | 1.74% | 95,000 +65,000 | +217% | +$20.1M |
|